Ironwood Announces Publication in The Lancet Gastroenterology & Hepatology of New Linaclotide Phase III Data in Children and Adolescents Aged 6-17 Years with Functional Constipation

– Newly published data highlights additional efficacy endpoints from trial –


– Linaclotide is the first and only FDA-approved prescription therapy for children and adolescents aged 6-17 years...

Related Keywords

Massachusetts ,United States ,Switzerland ,Boston ,China ,Rome ,Lazio ,Italy ,Japan ,Georgee Batchelor , ,Ironwood Pharmaceuticals Nasdaq ,Jerome Foundation ,University Of Miami Health System ,University Of Miami ,Ironwood Pharmaceuticals Inc ,National Population Projection Tables ,Drug Administration ,Division Of Pediatric Gastroenterology ,Linkedin ,Ironwood Pharmaceuticals ,Astrazeneca ,Nasdaq ,Lancet Gastroenterology ,Miguel Saps ,Pediatric Gastroenterology ,Endowed Chair ,Miami Health ,Common Adverse Reactions ,Prescribing Information ,Boxed Warning ,Childhood Functional Gastrointestinal Disorders ,Functional Gastrointestinal Disorders ,Population Projection Tables ,Functional Defecation Disorders ,Systemic Review ,Markets ,